Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

× No keyword cloud information.

46 in total

1. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors: C Reading; M Cole
Journal: Antimicrob Agents Chemother Date: 1977-05 Impact factor: 5.191

2. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.

Authors: K Coleman; D R Griffin; J W Page; P A Upshon
Journal: Antimicrob Agents Chemother Date: 1989-09 Impact factor: 5.191

3. Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics.

Authors: P J Wu; K Shannon; I Phillips
Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191

4. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa.

Authors: J C McLaughlin; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; M A Pfaller
Journal: J Antimicrob Chemother Date: 1994-02 Impact factor: 5.790

5. Mutual pro-drugs of beta-lactam antibiotics and beta-lactamase inhibitors.

Authors: B Baltzer; E Binderup; W von Daehne; W O Godtfredsen; K Hansen; B Nielsen; H Sørensen; S Vangedal
Journal: J Antibiot (Tokyo) Date: 1980-10 Impact factor: 2.649

6. In-vitro activity of cefoperazone-sulbactam against Bacteroides species.

Authors: M B Souza Dias; N V Jacobus; F P Tally
Journal: J Antimicrob Chemother Date: 1986-10 Impact factor: 5.790

7. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients.

Authors: G P Bodey; L S Elting; J Narro; C Koller; S O'Brien; E Estey; R Benjamin
Journal: J Antimicrob Chemother Date: 1993-07 Impact factor: 5.790

8. [Sulbactam in combination with mezlocillin, piperacillin or cefotaxime. Clinical and bacteriological results in the treatment of severe bacterial infections].

Authors: K Manncke; M Springsklee; W R Heizmann; H G Sonntag
Journal: Med Klin (Munich) Date: 1991-09-15

9. Antibacterial activity of ticarcillin in the presence of clavulanate potassium.

Authors: R Sutherland; A S Beale; R J Boon; K E Griffin; B Slocombe; D H Stokes; A R White
Journal: Am J Med Date: 1985-11-29 Impact factor: 4.965

10. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.

Authors: R N Jones; H W Wilson; C Thornsberry; A L Barry
Journal: Diagn Microbiol Infect Dis Date: 1985-11 Impact factor: 2.803

3 in total

1. Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be.

Authors: L S Tzouvelekis; M Gazouli; E E Prinarakis; E Tzelepi; N J Legakis
Journal: Antimicrob Agents Chemother Date: 1997-02 Impact factor: 5.191

Review 2. Rational prescribing of antibacterials in hospitalised children.

Authors: J E Hoppe
Journal: Pharmacoeconomics Date: 1996-12 Impact factor: 4.981

Review 3. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors: C M Perry; A Markham
Journal: Drugs Date: 1999-05 Impact factor: 9.546

3 in total